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Abstract
Pulmonary arterial hypertension (PAH) is a fatal disease without a cure. If 
untreated, increased pulmonary vascular resistance kills patients within several 
years due to right heart failure. Even with the currently available therapies, survival 
durations remain short. By the time patients are diagnosed with this disease, the 
damage to the right ventricle (RV) has already developed. Therefore, agents that 
repair the damaged RV have therapeutic potential. We previously reported that 
cardiac fibrosis that occurs in the RV of adult Sprague–Dawley rats with PAH could 
naturally be reversed. We herein investigated the mechanism of this remarkable 
cardiac repair process. Counting of cardiomyocytes showed that the elimination 
of cardiac fibrosis is associated with the increased RV myocyte number, suggest-
ing that new cardiomyocytes were generated. Immunohistochemistry showed the 
expression of α-smooth muscle actin and Sox-2 in RV myocytes of rats with PAH. 
Transmission electron microscopy detected the structure that resembles maturing 
cardiomyocytes in both the RV of PAH rats and cultured cardiomyocytes derived 
from induced pluripotent stem cells. We propose that the damaged RV in PAH can 
be repaired by activating the cell reprogramming mechanism that converts resident 
cardiac fibroblasts into induced cardiomyocytes.
Keywords: cardiac repair, cardiomyocyte regeneration, cell reprogramming, 
pulmonary hypertension, right ventricle
1. Introduction
Pulmonary arterial hypertension (PAH) affects males and females of any age, 
including children. Despite the availability of approved drugs, PAH remains a 
fatal disease without a cure [1, 2]. The major pathogenic features that increase the 
pulmonary vascular resistance in PAH include the vasoconstriction and the devel-
opment of vascular remodeling, in which pulmonary artery (PA) walls are thick-
ened and the lumens are narrowed or occluded. Increased resistance puts strain on 
the right ventricle (RV), and right heart failure is the major cause of death among 
PAH patients [3, 4]. The median overall survival for patients diagnosed with PAH is 
2.8 years from the time of diagnosis (3-year survival: 48%) if untreated [5, 6]. Even 
with currently available therapies, the prognosis remains poor with only 58–75% of 
PAH patients surviving for 3 years [7–10]. PAH is a progressive disease; and by the 
time patients are diagnosed, RV damage has often already occurred.
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RV failure is the major cause of death among patients with PAH. However, no 
treatment strategies are available to manage the RV dysfunctions. Physiologically, 
the RV needs to cope with fold changes in PA pressure. Thus, the RV is capable of 
adapting to increased pressure. Similarly to human patients with PAH, we found 
that the RV of Sprague–Dawley (SD) rats treated with SU5416 and hypoxia to 
produce PAH suffer from severe cardiac fibrosis at 8 to 17 weeks after the initiation 
of the SU5416/hypoxia treatment [11]. Remarkably, at 35 weeks after the initiation 
of the SU5416/hypoxia treatment, RV fibrosis was found to be resolved in these 
rats, despite the RV pressure remained high [12]. Thus, the RV remodeling can 
naturally be reversed in these animals, providing an interesting model of RV repair. 
Understanding the mechanism of such naturally occurring events should shed a 
light on developing therapeutic strategies to repair the cardiac damage in human 
patients. The present study examined the mechanism of this cardiac repair process.
2. Materials and methods
2.1 Experimental animals
Male adult SD rats (Charles River Laboratories International, Inc., Wilmington, 
MA, USA) were subcutaneously injected with SU5416 (20 mg/kg body weight; 
MedChem Express, Monmouth Junction, NJ, USA), maintained in hypoxia for 
3 weeks [11, 12] and then in normoxia for up to 32 weeks (35-week time points). 
Animals were subjected to hypoxia in a chamber (30”w x 20”d x 20”h) regulated 
by an OxyCycler Oxygen Profile Controller (Model A84XOV; BioSpherix, Redfield, 
NY, USA) set to maintain 10% O2 with an influx of N2 gas, located in the animal 
care facility at the Georgetown University Medical Center [11, 12]. Ventilation to 
the outside of the chamber was adjusted to remove CO2, such that its level did not 
exceed 5000 ppm. Control animals were subjected to ambient 21% O2 (normoxia) 
in another chamber. Animals were fed normal rat chow. Animals were anesthetized 
and euthanized by excising the heart and the lungs.
The Georgetown University Animal Care and Use Committee approved all 
animal experiments, and the investigation conformed to the National Institutes of 
Health (NIH) Guide for the Care and Use of Laboratory Animals.
2.2 Immunohistochemistry (IHC)
RV tissues were immersed in buffered 10% formalin at room temperature, 
and were embedded in paraffin. These paraffin-embedded tissues were cut 
and mounted on glass slides. IHC was performed using horseradish peroxidase 
(HRP) labeled polymer and 3,3′-diaminobenzidine (DAB) chromagen (Agilent 
Technologies, Santa Clara, CA, USA) with α-smooth muscle actin (αSMA; Catalog 
# ab32575) and Sox2 (Catalog # ab97959) antibodies (Abcam, Cambridge, UK).
2.3 Transmission electron microscopy (TEM)
The RV free wall tissues of rats subjected to SU5416/hypoxia as well as cultured 
cardiomyocytes derived from human induced pluripotent stem cells (iPSCs) 
purchased from Cell Applications, Inc. (San Diego, CA) were fixed in the 2.5% glu-
taraldehyde/0.05 M cacodylate solution, post-fixed with 1% osmium tetroxide and 
embedded in EmBed812. Ultrathin sections (70 nm) were post-stained with uranyl 
acetate and lead citrate and examined in the Talos F200X FEG transmission electron 
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microscope (FEI, Hillsboro, OR, USA) at 80 KV located at the George Washington 
University Nanofabrication and Imaging Center. Digital electron micrographs were 
recorded with the TIA software (FEI).
2.4 Statistical analysis
Means and standard errors were calculated. Comparisons between three groups 
were analyzed by using one-way analysis of variance (ANOVA) with a Student–
Newman–Keuls post-hoc test using the GraphPad Prism (GraphPad Software, Inc., 
La Jolla, CA, USA). P < 0.05 was considered to be significant.
3. Results
Since the initial discovery that treating SD rats with the SU5416 injection 
plus chronic hypoxia promoted severe PAH with pulmonary vascular lesions that 
resemble those of human patients [13], this experimental model has become a 
gold standard in the research field of PAH. Experimental design usually involves 
the single subcutaneous injection of SU5416, followed by subjecting to chronic 
hypoxia for 3 weeks. In many studies, rats are then maintained in normoxia for 2 
to 5 weeks, and PAH and pulmonary vascular remodeling are observed [13–17]. At 
this stage, some laboratories including ours have reported that the RV is severely 
damaged with fibrosis [11, 14, 18, 19]. At 8 to 17 weeks after the SU5416 injec-
tion, however, we found that, despite the occurrence of severe fibrosis, the RV 
contractility is maintained or even improved, perhaps due to the formation of 
‘super’ RV myocytes [11]. Moreover, our more recent results demonstrated that, 
at 35 weeks (3 weeks hypoxia followed by 32 weeks of normoxia), RV fibrosis 
was largely resolved, despite the RV pressure remained high [12]. The number of 
myofibroblasts that contribute to the formation of fibrosis, as detected using a 
well utilized marker αSMA, is increased in non-vessel regions of the RV of SD rats 
with severe PAH as well as RV fibrosis, and this expression declined in rats with 
repaired RV at 35 week after the SU5416 injection [12]. Thus, the SU5416/hypoxia 
treatment does not cause the death of SD rats and the damaged RV can be repaired 
naturally. Since RV myocytes were not hypertrophied at 35-weeks, the number of 
myocytes must have been increased to fill the post-fibrotic areas. Indeed counting 
cardiomyocytes indicated that, compared to the 17-week time point when fibrosis 
was present, the number of cardiomyocytes increased at 35-weeks when the RV 
was repaired (Figure 1).
Based on these results, we hypothesize that these SD rats possess a mechanism 
that repairs the damaged heart in response to PAH. This raises a question on where 
regenerated cardiomyocytes come from when the RV repair occurs. It is now known 
that some adult cardiomyocytes are capable of proliferating [20]. However, the car-
diac renewal through the cardiomyocyte proliferation would be too slow to replace 
large fibrotic areas that were seen in our experimental model. Another possibility 
is that new cardiomyocytes were regenerated from cardiac progenitor cells. We 
have identified c-kit and isl1-positive cardiac progenitor cells in the RV of SD rats, 
however, their levels were not altered in PAH rats (data not shown).
Our previous experiments described in Zungu-Edmondson et al. [12] using 
the αSMA antibody were originally performed for the purpose of detecting 
myofibroblasts, which express αSMA. By examining αSMA IHC slides from RVs 
of SD rats with PAH (at 17-weeks) with a larger magnification (x1,000) as shown 
in Figure 2A of Zungu-Edmondson et al. [12], we noticed that some brown 
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αSMA stains, in addition to myofibroblasts indicated by arrows, also occurred 
on cardiomyocytes. We initially discarded these observations by thinking that 
they are non-specific artifacts. However, further examinations of a number of 
IHC slides made us convinced that cardiomyocytes are indeed stained with the 
αSMA antibody. This seems to occur regionally as a group in the myocardial 
walls (Figure 2A). Figure 2B shows the amplified view of Figure 2A clearly 
demonstrating that these cardiomyocytes with clear striations express αSMA. By 
Figure 2. 
Discovery of naturally-occurring induced cardiomyocytes (iCMs)? SU5416-injected SD rats were subjected to 
3 weeks hypoxia and then maintained in normoxia to promote PAH. 17 weeks after the injection, myocardium 
tissues were fixed in formalin, embedded in paraffin, and subjected to IHC using the antibody against αSMA 
(brown stains). (A and B) αSMA IHC results shown at x200 and x1,000 magnifications, which clearly show 
the brown stains in RV cardiomyocytes of SD rats with PAH. (C) This brown αSMA stain was not observed in 
control rat RVs without PAH. Scale bars indicate 200 μm for x200 and 50 μm for x1,000.
Figure 1. 
Restoration of RV cardiomyocytes. SU5416-injected SD rats were subjected to 3 weeks hypoxia and then 
maintained in normoxia to promote PAH. 17 and 35 weeks after the SU5416 injection, RV myocardium tissues 
were fixed in formalin, embedded in paraffin, and subjected to H&E staining. The number of cardiomyocytes 
were counted and expressed as % of the control rats (Cont). SD rats with PAH at 17 weeks after the initiation 
of SU5416/hypoxia had significantly reduced RV myocyte number compared to healthy controls. This decrease 
in RV myocyte number was restored at 35 weeks. The symbol * denotes that the values are significantly different 
from each other at p < 0.05.
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contrast, control RVs from healthy rats without PAH did not exhibit the staining 
of cardiomyocytes with the αSMA antibody (Figure 2C).
Cell reprogramming is defined as the conversion of one specific cell type to 
another. This technology has gained considerable attention when Prof. Shinya 
Yamanaka discovered the means to convert fibroblasts into iPSCs and received the 
Nobel Prize [21]. In their study, stem cell-related transcription factors including 
Oct4 and Sox2 were used to convert somatic cells to pluripotent cells that can be 
differentiated into various cell types including cardiomyocytes [22]. More recently, 
a combination of cardiac-specific transcription factors was found to directly 
convert fibroblasts into cardiomyocytes [23, 24]. Figure 3A shows our TEM study 
of cardiomyocytes derived from iPSCs. These induced cardiomyocytes (iCMs) 
are capable of beating, express contractile proteins, and exhibit an organized 
sarcomere structure with clear striations and Z-lines (Figure 3A). In addition, 
some regions with the not well-defined sarcomere organization, which could be 
in the process of maturing into iCMs were also identified in these TEM images 
(Figure 3B). iCMs have been shown to express αSMA [25], while normal adult 
cardiomyocytes do not. Thus, αSMA-positive cardiomyocytes we observed in adult 
SD rats with PAH could be iCM-like cells. Consistently with this hypothesis, our 
examination of TEM images revealed that the structure resembling cardiomyocytes 
maturing from iPSCs as observed in cultured cells (Figure 3B) also occurs in the 
RV of SD rats with PAH (Figure 4B).
These results would support the concept that RVs of SD rats with PAH  
have iCMs-like cells that are produced via cell reprogramming. However, the αSMA 
expression can be induced by the fetal gene program mechanism that is associated 
with cardiac hypertrophy, independent of cell reprogramming. Thus, we exam-
ined if factors more directly related to cell reprogramming are expressed in these 
cardiomyocytes. We found that cardiomyocytes of RV tissues from SD rats with 
PAH also express Sox2 (Figure 5A and B), a stem cell-related transcription factor 
that has been used to generate iPSCs [22]. By contrast, no Sox2 stains were observed 
in healthy control SD rats without PAH (Figure 5C).
Figure 3. 
TEM image of cardiomyocytes derived from iPSCs. The reprogramming technology was used to convert cultured 
human fibroblasts into iPSCs, then to cardiomyocytes (cell applications, Inc.). Fixed iPSC-derived cardiomyocytes 
were observed under a transmission electron microscope. (A) the representative image shows cardiomyocytes 
with clear striations and sarcomere structures (arrow), indicating that iPSCs indeed can become matured 
cardiomyocytes. Magnification, x5,500. (B) we also identified some regions with the not well defined sarcomere 
organization (arrows), which may be in the process of maturing into cardiomyocytes. Magnification, x14,000.
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4. Discussion
In response to pressure overload, the heart ventricles undergo a series of adap-
tive events. In response to systemic and pulmonary hypertension, the left ventricle 
(LV) and the RV, respectively hypertrophy in order to increase the force of muscle 
contraction. Concentric hypertrophy is the first change that occurs in response to 
chronic pressure overload, and this compensatory mechanism allows for improved 
cardiac output. Exercise-induced cardiac hypertrophy, for example, increases the 
force of contraction in accordance the needs associated with strenuous exercise 
and training. This adaptive feature is reversible. However, in chronic disease 
conditions, this compensatory mechanism thickens the ventricular wall too much 
in a manner that decreases the stroke volume and thus the cardiac output. This 
results in the second adaptation to decrease the ventricular wall thickness. In case 
of the LV, the transition from concentric to eccentric hypertrophy predominates, 
Figure 5. 
Expression of Sox2. SU5416-injected SD rats were subjected to 3 weeks hypoxia and then maintained 
in normoxia to promote PAH. 17 weeks after the injection, hearts were fixed and subjected to IHC with 
the antibody against Sox2 (brown stains). (A and B) Sox2 IHC results shown at x200 and at x1,000 
magnifications, which clearly show the brown stains in RV cardiomyocytes of SD rats with PAH. (C) This 
brown Sox2 stain was not observed in control rat RVs without PAH. Scale bars indicate 200 μm for x200 and 
50 μm for x1,000.
Figure 4. 
TEM identification of maturing ICM-like cells in the RV of PAH rats. SD rats were injected with SU5416, 
subjected to 3 weeks hypoxia, and maintained in normoxia. 20 weeks after the injection, RV tissues were 
fixed and analyzed by TEM. (A) the image shows normal cardiomyocytes with clear striations and sarcomere 
structures (arrow). Magnification, x5,500. (B) we also identified some regions with the not well defined 
sarcomere organization (arrows), which may be in the process of maturing into iCMs, similar to the structure 
shown in Figure 3B. Magnification, x14,000.
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resulting in the dilated LV with the thin ventricular wall. This event, however, 
does not seem to occur in the RV in response to chronic pulmonary hypertension 
and the hallmark of cor pulmonale is that the RV myocytes remain concentrically 
hypertrophied at the time of heart failure. In the RV, the attempt to decrease the 
RV wall thickness is expected to be related to the promotion of cell death, although 
it is unclear whether apoptosis really occurs in the RV of human patients with pul-
monary hypertension [26]. However, apoptotic cardiomyocytes have been detected 
in the RV of a rat model of pulmonary hypertension [11]. In these rats, regions of 
the RV where cardiomyocytes die get filled with fibrosis.
Using well-studied model of PAH, in which SD rats are treated with the SU5416 
injection and chronic hypoxia, we previously found that RVs were capable of 
maintaining sufficient force of muscle contraction even severe fibrosis occurred at 8 
to 17 weeks after the initiation of the SU5416/hypoxia treatment [11]. We postulated 
that this is due to the formation of “super RV myocytes” that are capable of elicit-
ing stronger force of contraction via a mechanism involving the downregulation of 
calsequestrin 2, the major Ca2+-binding protein of the sarcoplasmic reticulum.
Further, remarkably at 35 weeks after the SU5416/hypoxia initiation, these fibro-
sis regions disappear and are filled with newly formed cardiomyocytes [12]. The 
present study indeed showed that the number of cardiomyocytes were increased at 
the 35-week time point, compared to the 17-week time point. This increased number 
of cardiomyocytes was found to be associated with the production of RV cardiomyo-
cytes that express αSMA and Sox2 as well as the occurrence of the structure visible 
in TEM that resembles maturing iCMs similar to those observed in cultured cardio-
myocytes derived from iPSCs. From these results, we hypothesize that the damaged 
RV due to PAH can naturally be repaired in SD rats through a mechanism that 
involves the conversion of resident cardiac fibroblasts into iCMs via cell reprogram-
ming (Figure 6). Our finding also suggests that the nature possesses the ability for 
maturing iCMs into functional cardiomyocytes that are capable of eliciting strong 
muscle contraction through a “functionalization” process (Figure 6). Our results 
so far provided evidence to support this novel mechanism of cardiac regeneration, 
however, further work is needed to prove this concept.
Understanding of the endogenous means to repair the heart is important, not 
only to provide basic knowledge of cardiac physiology, but also to develop thera-
peutic strategies to treat conditions in which cardiomyocytes are damaged. Along 
with the cardiomyocyte proliferation and the involvement of cardiac progenitor 
cells, our results suggest a novel mechanism of cardiac regeneration through cell 
reprogramming. Defining this naturally occurring mechanism should contribute to 
the development of technologies to convert resident cardiac fibroblasts into cardio-
myocytes to save lives.
Figure 6. 
Scheme depicting our hypothesis. SD rats possess an RV repair mechanism, in which naturally occurring cell 
reprogramming process converts resident fibroblasts into αSMA-and Sox2-positive induced cardiomyocytes 
(iCMs). These rats also possess the functionalization mechanism that makes functional cardiomyocytes that can 
elicit strong muscle contraction.
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5. Conclusion
The present study generated evidence to support a fascinating and novel mecha-
nism of naturally occurring cardiac repair that should be important for the develop-
ment of effective therapeutic strategies to treat cardiac failure. This novel mechanism 
involves the conversion of resident cardiac fibroblasts into iCMs through the cell 
reprogramming process that appears to share events occurring in iPSC biology.
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